Section 3 of 6
Product information and disease description
63 evidence topics · 51 sources
Product description
Phase of product development
Product, sponsor, indication, and FDA orphan status: designation and approval status
| Field | Source quotation |
|---|---|
| Orphan designation | “Treatment of Stargardt disease” |
| Date designated | “09/19/2017” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
Regulatory status: Under review; NDA submitted June 2026
FDA acceptance, review designation, and target action date
Additional regulatory designations
Product information
Generic, brand name and therapeutic class of product
Product, sponsor, indication, and FDA orphan status: product and sponsor
| Field | Source quotation |
|---|---|
| Generic name | “tinlarebant” |
| Sponsor | “Belite Bio, LLC” |
Names, drug class, and proposed mechanism of action: names and class
Dosage forms and strengths
Investigational dosage form
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
No evidence found.
Indication
Investigational indication: orphan designation
Pharmacology
Mechanism of action
Names, drug class, and proposed mechanism of action: retinol delivery
Pharmacodynamics
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Adolescents and young adults: studied age range
Hepatic and renal impairment
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on Tinlarebant
Pharmacokinetics and drug interactions: coadministration
Publication recommendation concerning CYP3A inducers: not approved labeling
Investigator conclusion on coadministration and food
“These data show that the pharmacokinetics of tinlarebant is not significantly altered by gastric acid suppression or food.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Dosing patients with tinlarebant and strong CYP3A inhibitors concurrently is unlikely to compromise safety based on its pharmacokinetic–pharmacodynamic relationships, but tinlarebant should be contraindicated with strong CYP3A inducers due to the risk of treatment failure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No unexpected safety signals occurred and tinlarebant was well tolerated in all participants.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Effects of Tinlarebant on other drugs
No evidence found.
Dosing and administration
Dosage
DRAGON: investigational dose
Administration
Access and distribution
Anticipated patient financial support
Co-prescribed/Concomitant therapies
No evidence found.
Effect of Tinlarebant on quality measures
No evidence found.
Product comparison
Place of product in therapy
Disease description
Definition and etiology
Inherited retinal disease
Epidemiology
Incidence of Stargardt disease type 1
Incidence and prevalence: Netherlands nationwide registry: incidence
Prevalence of Stargardt disease type 1
Estimated U.S. patient population
Incidence and prevalence: Netherlands nationwide registry: prevalence
“point prevalence in 2018 was approximately 1:22,000‐1:19,000” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“with and without 10% of potentially unregistered cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history, survival, and mortality
Clinical course and visual prognosis: variability
ProgStar report no. 10: visual acuity change over 24 months
ProgStar report no. 17: progression of definitely decreased autofluorescence
Age at onset and prognosis by onset age
“Patients with Stargardt disease demonstrate a progressive impairment of visual acuity (VA), which often begins within the first or second decades of life; however, both early and later adult-onset Stargardt disease also are observed, with later onset being associated with a better prognosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ProgStar report no. 1: baseline disease severity in the natural history cohorts
“Three hundred sixty-five unique patients aged 6 years and older at baseline harboring disease-causing variants in the ABCA4 gene and with specified ocular lesions were enrolled from 9 centers in the United States and Europe.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At baseline, 36% had no or mild VA loss, and 47% of the study eyes had areas of definitely decreased autofluorescence (DDAF) with an average lesion area of 2.5±2.9 mm² (range, 0.02–16.03 mm²).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At baseline, 20% had no or mild VA loss, and 64% had areas of DDAF with an average lesion area of 4.0±4.4 mm² (range, 0.03–24.24 mm²).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The ProgStar cohorts have baseline characteristics that encompass a wide range of disease severity and are expected to provide valuable data on progression based on serial quantitative measurements derived from multiple methods, which will be critical to the design of planned clinical trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Diagnosis
Clinical and molecular diagnostic assessment
Mesopic microperimetry in Stargardt disease: application and reliability
Clinical presentation - signs and symptoms
Central vision: progressive visual loss
Long-term morbidity
Clinical course and visual prognosis: long-term acuity
Burden of Stargardt disease type 1
Humanistic burden and health-related quality of life
Vision-specific quality of life and functional vision: Brazil
“41 patients with STGD and 46 healthy volunteers” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with STGD had significant impairment of vision-specific QoL and functional vision compared with controls” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mental health outcomes in inherited retinal diseases: Stargardt disease subgroup
Patient-reported outcome measures in recessive Stargardt disease
“Properties of Patient-Reported Outcome Measures in Recessive Stargardt Disease” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The NEI VFQ and IVI have acceptable psychometric properties in STGD1” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Daily functioning, independence, and caregivers: daily functioning
Economic burden and healthcare resource utilization
Direct healthcare costs: U.S. outpatient claims
“Outpatient administrative claims data (2010–2014)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The payment per year of insurance coverage for SD (median: $105.58, IQR: $50.53-$218.71)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-of-illness studies of inherited retinal diseases: systematic review
Economic impact of Stargardt disease type 1 on families
Daily functioning, independence, and caregivers: caregiver needs
Patient testimony: costs of assistive technology
Economic impact of diagnostic testing
South Africa: time-limited 2025 genetic-testing offer
South Africa: additional genetic-counseling consultation cost
Approaches to treatment
Current treatment options and standard of care
Low-vision aids and vision rehabilitation
Stargardt disease: patient-care guidance: low-vision care
Lifestyle and light-exposure management
Stargardt disease: patient-care guidance: vitamin A supplementation
Genetic counseling
Limitations of current therapies
Summary
Current care includes low-vision aids, vision rehabilitation, and measures to limit avoidable retinal stress. The National Eye Institute describes no treatment for Stargardt disease, while the 2026 management review identifies supportive care as foundational. The 2018 technology assessment reported limitations in the size, duration, and quality of studies available at that time; it predates the completed DRAGON trial.
Treatments for dry age-related macular degeneration and Stargardt disease
Place in treatment, anticipated use, and care setting
Summary
Tinlarebant is being developed as an oral treatment for Stargardt disease type 1. DRAGON studied participants aged 12–20 years with established atrophic lesions and visual acuity of 20/200 or better. This trial population should not be equated with a finalized approved population. The sponsor anticipates confirmatory ABCA4 testing, specialty-pharmacy fulfillment, and patient-support programs. These are proposed access arrangements rather than an approved care pathway.
Heterogeneity of treatment effect
No evidence found.
Care management intervention strategies
Stargardt’s Connected Research Network inaugural meeting report
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.